Grading of neurological toxicity in patients treated with tisagenlecleucel in the JULIET trial.
Sign Up to like & getrecommendations! Published in 2020 at "Blood advances"
DOI: 10.1182/bloodadvances.2019001305
Abstract: Chimeric antigen receptor-T (CAR-T) cell therapy achieves durable responses in patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL), but may be associated with neurological toxicity (NT). We retrospectively assessed differences and concordance among 3… read more here.
Keywords: trial; juliet trial; neurological toxicity; therapy ... See more keywords